8/30/2023 0 Comments Cdc up to date vaccinePrimary series completion and up-to-date COVID-19 vaccination status were assessed among all adolescents (4,383 ) and adults (99,056 ). Bivalent booster dose receipt and intention to receive (or have child receive) a booster dose were assessed among the subset of respondents who had completed the primary COVID-19 vaccination series ( 5) (2,900 83,462 ). The cumulative NIS-CCM and NIS-ACM response rates as of December 2022 were 18.2% and 23.2%, respectively. Thus, a booster vaccination received after September 1, 2022, was assumed to be a bivalent booster. Receipt of an updated bivalent booster was not explicitly asked of respondents however, only bivalent boosters were authorized after Septem( 3). Data collected during October 30–December 31, 2022,* were analyzed to assess demographic, behavioral, and social factors associated with COVID-19 primary series vaccination, †, §, ¶ bivalent booster receipt,**, ††, §§ up-to-date COVID-19 vaccination status, ¶¶ and, among adults or their children who had not received a bivalent booster dose, intent to receive booster vaccination or to get their child a booster vaccination. NIS-CCM and NIS-ACM data were collected by telephone interview in English, Spanish, or other languages using a random-digit–dialed sample of cellular telephone numbers. Health care provider recommendations for COVID-19 vaccination dissemination of information by trusted messengers about the continued risk for COVID-19–related illness and the benefits and safety of bivalent booster vaccination and reducing barriers to vaccination could improve COVID-19 bivalent booster coverage among adolescents and adults. Although bivalent booster vaccination coverage among adults differed by factors such as income, health insurance status, and social vulnerability index (SVI), these factors were not associated with differences in reluctance to seek booster vaccination. Among adolescents with parents who were open to getting a booster vaccination for their child, 32.4% had not received a provider recommendation for any COVID-19 vaccination, and 11.8% had parents who reported safety concerns. Among adults who were open to receiving booster vaccination, 58.9% reported not having received a provider recommendation for booster vaccination, 16.9% had safety concerns, and 4.4% reported difficulty getting a booster vaccine. Bivalent booster coverage was lower among non-Hispanic Black or African American (Black) and Hispanic or Latino (Hispanic) adolescents and adults compared with non-Hispanic White (White) adolescents and adults. Adolescents and adults in rural areas had a much lower primary series completion rate and up-to-date vaccination coverage. Based on data collected during October 30–December 31, 2022, from the National Immunization Survey–Adult COVID Module (NIS-ACM) ( 4), 27.1% of adults who had completed a COVID-19 primary series had received a bivalent booster, 39.4% had not yet received a bivalent booster but were open to receiving booster vaccination, 12.4% had not yet received a bivalent booster and were unsure about getting a booster vaccination, and 21.1% were reluctant to receive a booster. Based on data collected during October 30–December 31, 2022, from the National Immunization Survey–Child COVID Module (NIS-CCM) ( 4), among all adolescents aged 12–17 years who completed a primary series, 18.5% had received a bivalent booster dose, 52.0% had not yet received a bivalent booster but had parents open to booster vaccination for their child, 15.1% had not received a bivalent booster and had parents who were unsure about getting a booster vaccination for their child, and 14.4% had parents who were reluctant to seek booster vaccination for their child. The bivalent booster is formulated to protect against the Omicron BA.4 and BA.5 subvariants of SARS-CoV-2 as well as the original (ancestral) strain ( 3). CDC recommended an updated (bivalent) booster for adolescents aged 12–17 years and adults aged ≥18 years on Septem( 3). COVID-19 vaccine booster doses are safe and maintain protection after receipt of a primary vaccination series and reduce the risk for serious COVID-19–related outcomes, including emergency department visits, hospitalization, and death ( 1, 2).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |